Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
Opass Putcharoen,1 Tanya Do,2 Anchalee Avihingsanon,2 Kiat Ruxrungtham1,2 1Department of Medicine, Faculty of Medicine, Chulalongkorn University, 2The HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, The Thai Red Cross AIDS Research Center, Bangkok, Thailand Abstract:...
Main Authors: | Putcharoen O, Do T, Avihingsanon A, Ruxrungtham K |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-10-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | https://www.dovepress.com/rationale-and-clinical-utility-of-the-darunavirndashcobicistat-combina-peer-reviewed-article-DDDT |
Similar Items
-
Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
by: Navarro J, et al.
Published: (2016-10-01) -
Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
by: Crutchley RD, et al.
Published: (2016-03-01) -
Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
by: Ruxandra-Cristina Marin, et al.
Published: (2021-03-01) -
Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
by: Squillace N, et al.
Published: (2018-10-01) -
Data on the stability of darunavir/cobicistat suspension after tablet manipulation
by: D. Zanon, et al.
Published: (2020-06-01)